Top Medical News
Jairia Dela Cruz, 12 hours ago
In extremely elderly Asian patients with early breast cancer, surgery yields survival outcomes that are similar to their younger counterparts and better compared with nonsurgical treatment, a Singapore study has shown.
13 hours ago
A recent study suggests that discontinuation of dexamethasone premedication after two uneventful infusions or reduction in the dose of dexamethasone paclitaxel premedication are both safe alternatives to high-dose steroid premedications recommended in product labelling.
16 hours ago
Metformin therapy appears to significantly improve prognosis in patients with colon cancer and survival in patients with lung cancer, a new study has shown.
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Tristan Manalac, Yesterday
Statin use, particularly in smokers, obese patients and nondiabetics, has a strong and dose-dependent association with decreasing risk of pancreatic ductal adenocarcinoma (PDAC), according to a new study.
Treatment with alphalitic and Odyliresin has significantly improved clinical parameters and uroflowmetry, and has substantially reduced adenoma volume and postvoid residual volume, in patients with benign prostatic hyperplasia-related lower urinary tract symptoms at 12 months, according to a recent study.
One or more relevant drug-drug interactions occur in some lung cancer patients treated with cytotoxic therapy, highlighting the importance of medication surveillance by a hospital pharmacist to prevent possible negative drug-drug interactions, suggests a recent study.
Special Reports
20 Sep 2017
Sustained stable disease with regorafenib in heavily pretreated metastatic colon cancer
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 14 May 2017
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
Conference Reports
Dr. Joseph Delano Fule Robles, 04 Oct 2017

The 5-year analysis of the ExteNET trial recently confirmed sustained benefit with neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer, according to results presented at the European Society for Medical Oncology (ESMO) 2017 Congress held in Madrid, Spain. 

Jenny Ng, 22 Sep 2017

Adjuvant nivolumab treatment significantly improved outcomes vs ipilimumab in patients with surgically resected stage III/IV melanoma, according to interim results of the CheckMate 238 trial. 

Elaine Tan, 21 Sep 2017

Rucaparib maintenance therapy increases progression-free survival (PFS) in BRCA-mutant recurrent ovarian cancer (OC) by 77 percent, according to late-breaking results from the ARIEL3 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. 

Elaine Tan, 21 Sep 2017
CT-based surveillance, recommended by major international guidelines during the first 2 years after complete resection of non-small-cell lung cancer (NSCLC), has demonstrated no significant overall survival (OS) benefit over less intensive surveillance with clinical examinations and chest X-rays (CXR) only, according to a study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.
Christina Lau, 18 Sep 2017

Patients with locally advanced cervical cancer should not be routinely treated with neoadjuvant chemotherapy (NACT) followed by surgery as this approach does not improve disease-free survival (DFS) or overall survival (OS) vs standard chemoradiotherapy (CRT), according to results of a phase III trial.

Jackey Suen, 18 Sep 2017

The risk of recurrence in patients with resected stage III BRAF-mutant melanoma can be reduced with adjuvant BRAF inhibitor and/or MEK inhibitor therapy, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.

Dr. Joseph Delano Fule Robles, 15 Sep 2017

Combination therapy with ramucirumab and docetaxel offers a progression-free survival (PFS) advantage over docetaxel alone in patients with advanced or metastatic urothelial carcinoma (UC), according to results of the phase III RANGE trial presented at the European Society of Medical Oncology  (ESMO) 2017 Congress held in Madrid, Spain. 

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!